Selected haemodynamically stable patients with acute pulmonary embolism could be treated at home. However, controversy persists about the optimal referral strategies and eligibility criteria for outpatient care. European guidelines recommend the PESI or sPESI score to assess the risk of all-cause mortality. If proper follow-up and anticoagulant therapy can be provided, patients with an sPESI score of 0 can be treated at home. The American guidelines do not require a predefined score and advise using pragmatic criteria, for example those formulated in the HESTIA Study.
Prof. Pierre-Marie Roy (University Hospital of Angers, France) presented the randomised, open-label, non-inferiority HOME-PE trial. The 1,974 normotensive participants, who presented to the emergency department with acute pulmonary embolism, were randomised to either the pragmatic HESTIA method or sPESI triage group:
- in the sPESI group, patients were eligible for outpatient care if the score was 0 (n=986); and
- in the HESTIA group, they were eligible for outpatient care if all 11 criteria were negative (n=984).
Patients who were not eligible for outpatient care were hospitalised. In both groups, the treating physician could overrule the decision on treatment location for medical or social reasons.
The primary endpoint, a composite of recurrent venous thromboembolism (VTE), major bleeding, and all-cause mortality within 30 days, occurred in 3.8% of patients in the HESTIA group and 3.6% in the sPESI group (P=0.005 for non-inferiority). Of note, a greater proportion of patients were eligible for home care using sPESI compared with HESTIA (48.4 vs 39.4%). However, the treating physician overruled sPESI more often than HESTIA. Consequently, a similar proportion of patients were discharged within 24 hours for home treatment (38.4 and 36.6%, respectively; P=0.42). In patients managed at home, the rate of complications was low.
The HOME-PE study showed that the HESTIA approach was non-inferior to the sPESI score as triaging strategy for outpatient care of patients with acute pulmonary embolism. Prof. Roy concluded, “These results support outpatient management of acute pulmonary embolism patients using either the HESTIA method or the sPESI score. In hospitals organised for outpatient management, both triaging strategies enable more than a third of pulmonary embolism patients to be managed at home with a low rate of complications.”
- Roy P-M. HOME-PE - Hospitalisation or Outpatient Management of PE Patients - HESTIA vs. Simplified PESI. Hot Line 3 session, ESC 2020 E-Congress, 31 Aug.
Posted on
Previous Article
« Antihypertensives also reduce CV risk in people with normal blood pressure Next Article
Low-dose colchicine reduces CV death and ischaemic events in coronary disease »
« Antihypertensives also reduce CV risk in people with normal blood pressure Next Article
Low-dose colchicine reduces CV death and ischaemic events in coronary disease »
Table of Contents: ESC 2020
Featured articles
2020 ESC Clinical Practice Guidelines
2020 Atrial Fibrillation Guidelines
2020 Non-ST-Segment Elevation Acute Coronary Syndromes Guidelines
2020 Sports Cardiology and Exercise in Cardiovascular Patients Guidelines
2020 Adult Congenital Heart Disease Guidelines
Hot Line Presentations
SGLT2 inhibitor improves cardiovascular outcomes in heart failure patients
First-in-class cardiac myosin inhibitor effective in obstructive hypertrophic cardiomyopathy
Reduced cardiovascular outcomes with early rhythm control
Trimetazidine after successful PCI not associated with fewer cardiac events
POPular TAVI: Aspirin-only antiplatelet strategy?
Reduced NT-proBNP in HFpEF with sacubitril/valsartan
DAPA-CKD: Dapagliflozin improves CKD survival ± diabetes
Low-dose colchicine reduces CV death and ischaemic events in coronary disease
Similar outcomes sPESI and HESTIA for pulmonary embolism triage
Antihypertensives also reduce CV risk in people with normal blood pressure
COVID-19: Continuing versus suspending ACE inhibitors and ARBs
Drug initiation strategy not associated with increased use of oral anticoagulants
Restrictive blood transfusion non-inferior and cost-effective strategy
Late-Breaking Science
Increased mortality with colchicine in patients with ACS
Rivaroxaban protects limbs and ischaemic events in CAD-PAD patients
Antisense APOC3 oligonucleotide lowers triglyceride and atherogenic lipoproteins
Antisense ANGPTL3 lowers triglycerides
Reduced progression of coronary atherosclerosis with icosapent ethyl
Digoxin improves symptoms in stable patients with permanent AF
SGLT2 inhibitor ertugliflozin shows similar mortality but fewer HF hospitalisations
COVID and Cardiovascular Disease
Risk factors for thromboembolism and bleeding in COVID-19: lessons from Wuhan
The Yale COVID-19 Cardiovascular Registry
COVID-19 treatments and the importance of randomised trials
Related Articles
November 5, 2020
Rivaroxaban protects limbs and ischaemic events in CAD-PAD patients
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com